Micro Market Research
+1-888-502-0539
US/CAN Toll Free

You are here :   Home     Healthcare     Biotechnology     Life Sciences Research     Drug Discovery    

Global In vitro drug discovery Market Research Report

In vitro drug discovery and In vivo drug discovery adds up to total Drug Discovery market.

In vitro drug discovery can be segmented by Submarkets and Technologies. Submarkets of this market are Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation, RNA Interference, Biomarkers, Stem cell research, Next Generation Sequencing (NGS), Cell based assays and High throughput screening. Technologies of this market are NGS Platforms/Consumables/Services and Genomics.

 

Key Questions Answered

  • What are market estimates and forecasts; which of In vitro drug discovery markets are doing well and which are not?
  •  

    What makes our report unique?

    • This reports provides most granular segmentation on Next Generation Sequencer (NGS), Metabolomics, Biobanking/Biopreservation and RNA Interference.
    • This report provides market sizing and forecast for the In vitro drug discovery market. It also provides market sizing and forecast along with the drivers/inhibitors/opportunity analysis for each of the micro markets.
    •  

      Audience for this report

      • Global In vitro drug discovery companies
      • Manufacturing Companies
      • Traders, distributors, and suppliers
      • Governmental and research organizations
      • Associations and industry bodies
      • Technology providers
show more
PRODUCT TITLE PUBLISHED
Cell based assays Cell based assays
Cell based assays and Next Generation Sequencer (NGS), Metabolomics,
Upcoming
High throughput screening High throughput screening
The global High Throughput Screening market was valued at $14.38 billion in 2013 and is expected to reach $20.58 billion by 2018, growing at a CAGR of 7.4% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland).  
Upcoming
High content analysis/Screening High content analysis/Screening
The global High Content Screening market was valued at $380.31 million in 2013 and is expected to reach $646.59 million by 2018, growing at a CAGR of 11.2% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments, consumables, software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), among others
Upcoming
North American High Content analysis/Screening North American High Content analysis/Screening
The North American High Content Screening market was valued at $161.8 million in 2013 and is expected to reach $280.7 million by 2018, growing at a CAGR of 11.7% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S).
Upcoming
European High content analysis/Screening European High content analysis/Screening
The European High Content Screening market was valued at $124.29 million in 2013 and is expected to reach $207.9 million by 2018, growing at a CAGR of 10.6% from 2013 to 2018. High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S).
Upcoming
Asian High content analysis/Screening Asian High content analysis/Screening
The Asian High Content Screening market was valued at $55.75 million in 2013 and is expected to reach $101.74 million by 2018, growing at a CAGR of 12.8% from 2013 to 2018.High Content Screening market segmentation primarily based on product types, the market is categorized into instruments (Imaging and Analysis HCS Systems, Flow Cytometers), consumables (Reagents and Assay kits, Microplates and other consumables) , software, and services. Based on applications, the high content screening market is segmented into primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. Among the various end users of high content screening, pharmaceutical and biotechnology companies lead the market. Major players in the market include Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), PerkinElmer (U.S.), and GE Healthcare (U.K), Olympus (Japan), Life Technologies (U.S.), EMD Millipore (Germany), BD Bioscience (U.S.), Definiens AG (Germany), Yokogawa Electric Corporation (Japan), and TTP Labtech (U.S).
Upcoming
North American High throughput screening North American High throughput screening
The North American High Throughput Screening market was valued at $6454.3 million in 2013 and is expected to reach $9046.8 million by 2018, growing at a CAGR of 7.0% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland).
Upcoming
European High throughput screening European High throughput screening
The European High Throughput Screening market was valued at $3794.7 million in 2013 and is expected to reach $5194.3 million by 2018, growing at a CAGR of 6.5% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland).
Upcoming
Asian High throughput screening Asian High throughput screening
The Asian High Throughput Screening market was valued at $2547.3 million in 2013 and is expected to reach $3931.2 million by 2018, growing at a CAGR of 9.1% from 2013 to 2018. High Throughput Screening market is primarily categorized by technology, product, end user, and application. By technology, the HTS market is categorized into ultra high throughput screening (uHTS), cell-based assays, lab-on-a-chip, label-free technology, and bioinformatics. By product, the HTS market is segmented into instruments, consumables/reagents, and software and services. By end user, the High Throughput Screening market is categorized into pharmaceutical, biotechnology, academia and government, contract research organizations, and others. By application, the High Throughput Screening market is classified into target identification, primary screening, toxicology, stem cell biology, and others. Major players in the market include Agilent Technologies, Inc. (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.) and Tecan Group (Switzerland).
Upcoming
9 of 9 items
9 reports | Show
Connect With Us
US/CAN : +1-888-502-0539